Pharma News, 2024

Data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study, the first and largest to focus on people who have early signs of Alzheimer’s disease but are not yet showing sy...

Lantern Pharma, a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and...

In a deal worth approximately $405 million, Danish drugmaker Pharmacosmos has agreed to acquire G1 Therapeutics and the latter company's flagship product Cosela.

Servier has expanded its IDH drug armamentarium with the FDA approval for an IDH1/2 dual inhibitor. The approval represents the first major treatment advance in low-grade brain cancer in more than two...

After BioMarin conducted a spring clean of its pipeline in April, the company has decided that it also needs to offload a preclinical gene therapy for a condition that causes heart muscles to thicken.

Eximia Research Network has announced the acquisition of Tidewater Clinical Research, marking a significant expansion of its national clinical trial site network.

A new pathway that is used by cancer cells to infiltrate the brain has been discovered by a team of Canadian and American research groups co-led by the Singh Lab at McMaster University. The research a...

Shares of Eli Lilly notched a 3.5% gain on Thursday, Aug. 1, after the company reported positive clinical trial results for its increasingly successful weight management treatment. It looks like c...

BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally “hard-to-drug” targets, today announced an expansion to its strategic collaboration and licensing ag...

The acquisition of Mirus Bio's transfection re-agents, such as TransIT-VirusGEN, will enhance Merck's upstream portfolio.

Eli Lilly  and Novo Nordisk  are the two big names dominating the anti-obesity market today. They've been generating billions in revenue from their treatments, and there's ...

Sanofi has announced a significant investment of €1.3bn ($1.4bn) to increase its insulin production capabilities with an expanded facility in Frankfurt, Germany.